Are there specific translational challenges in regenerative medicine? Lessons from other fields

John Gardner, Alex Faulkner, Aurélie Mahalatchimy, Andrew Webster

Research output: Contribution to journalReview ArticleResearchpeer-review

39 Citations (Scopus)

Abstract

There is concern that translation 'from bench to bedside' within regenerative medicine (RM) will fail to materialize, or will be dismally slow, due to various challenges arising from the highly novel and disruptive nature of RM. In this article, we provide a summary of these challenges, and we critically engage with the notion that such challenges are specific to RM. It is important, we argue, not to overstate the exceptional nature of RM, as valuable lessons can be learned from elsewhere in medicine. Using several examples of technology adoption, we suggest that emerging RM products and procedures will have to work hard to find or create an adoption space if translation into the clinic is to be successful.

Original languageEnglish
Pages (from-to)885-895
Number of pages11
JournalRegenerative Medicine
Volume10
Issue number7
DOIs
Publication statusPublished - 1 Oct 2015
Externally publishedYes

Keywords

  • adoption space
  • clinical trials
  • manufacturing
  • regulation
  • reimbursement
  • technology adoption
  • translational challenges
  • translational medicine

Cite this